Latest Cleanspace (ASX:CSX) News

CleanSpace's AGILE respirator has achieved AS/NZS 17420.2:2021 certification, paving the way for commercialisation in Australia and New Zealand alongside its recent European approval.

A brutal sell-off in a few small caps sat alongside takeover bids, fresh capital raisings and strong gains in medtech. The week split the market in two: buyers chased clear funding and approval news, while weaker stories sank fast after reopening.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

CleanSpace Holdings posted a robust 26% revenue increase in FY25, turning the corner to positive EBITDA and cash flow in the second half, driven by strong industrial market demand and operational efficiencies.

CleanSpace Holdings Limited reported a 26% increase in revenue to $19.8 million for FY25, alongside a significant reduction in net loss to $478,276. The company’s strategic expansion and innovation efforts underpin its improving financial health and global market presence.

CleanSpace Holdings reports a robust 26% increase in FY25 revenue, driven by strong growth across Europe, North America, and APAC regions, underscoring its expanding footprint in industrial respiratory protection.